skip to Main Content

One of the cornerstones of TAG’s work is weighing in on mission-related issues by sending comment letters to a variety of organizations, including Federal agencies, Senate and House committees, Pharmaceutical companies, and the WHO. Various staff members also frequently testify in person at committee hearings, and submit written testimony.

2020 Letters

Public Comment for Draft Guidance on Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products
March 20, 2020 — TAG submitted comments in response to FDA Draft Guidance on Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products. Further guidance for research on treatments for rare diseases is needed, but stringent regulatory authority and quality clinical trial design must not be sacrificed in the name of expediency.

Leading Community Activists and Epidemiologists Demand NYC Take Stronger Action to Mitigate COVID-19 Outbreak
March 9, 2020 — TAG, PrEP4ALL and a number of other organizations/individuals sent this letter to New York City Mayor Bill DeBlasio, Council Speaker Corey Johnson, and Health Commissioner Oxiris Barbot. It demands immediate transparency on, and public involvement in, their response to the COVID-19 outbreak, and requests a conversation with the staff of all three offices as soon as possible.

Letter to USPTO Opposing Gilead’s Patent Term Extension Request for TAG
January 31, 2020 — Treatment Action Group (TAG) joined 36 other organizations who signed on to this letter to the US Patent and Trademark Office (USPTO), opposing Gilead’s request for a patent term extension for tenofovir alafenamide (TAF). The letter also supports a recent petition submitted by PrEP4All, based on evidence that Gilead intentionally delayed development of TAF for approximately six years in order to maximize profits from another compound. TAG urges the USPTO to reject Gilead’s request and allow for greater access to TAF.

TAG Comment on the Trans-NIH Strategic Plan Goals for Sexual & Gender Minority (SGM) Health Research
January 24, 2020 — TAG submitted this public comment in response to a Request for Information on the Development of the Fiscal Year 2021-2025 Trans-NIH Strategic Plan for Sexual & Gender Minority Health Research, affirming the need for a research agenda that will best address HIV, TB, and HCV among LGBTQ+ communities and incorporate equity and justice in all such research.

Open Letter: Time to Lower the Price of Xpert Cartridges to $5
January 6, 2020 — TAG joined 156 organizations and individuals to demand that Cepheid lower the price of Xpert tests for TB, HIV, HCV and other diseases to improve access to rapid, accurate diagnostic testing.

TAG Submission, OHCHR-CESCR’s Draft General Comment on Science
January 2, 2020 — The UN Office of the High Commissioner for Human Rights (OHCHR) via the Committee on Economic, Social , and Cultural Rights (CESCR) asked for general comments on the “right to science.” TAG submitted these comments and welcomes this landmark draft. We believe that future revisions must stress governmental obligation to direct resources to purposive development of science and technology, informed by the needs of marginalized communities.

Back To Top